The FDA recommends that health care providers evaluate the risks and benefits of continuing Copiktra vs prescribing an alternative therapy.
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
Among patients with AIDS-related lymphoma, hypoalbuminemia is linked to worse overall survival and progression-free survival.
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
The arsenic level in drinking water was negatively associated with incidences of lymphoma and leukemia in men and women.
The prevalence of pregnancy with cancer increased 13.8% from 2016 to 2019.
Two treatment-related factors and the frequency of 6 cell types were associated with response to COVID-19 vaccination.
In its ruling, the court challenged the Trump-era finding that glyphosate was not a serious health risk and “not likely” to cause cancer.
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
Among the TEAEs of clinical interest, the most frequent were infections, bleeding, cardiac events, anemia, and neutropenia and neutrophil count decrease.
Parsaclisib is a potent, highly selective, next-generation phosphoinositide 3-kinase-delta (PI3K-delta) inhibitor.
Based on preliminary data from this study, sugemalimab was granted breakthrough therapy designation for adult patients with R/R ENKTL in 2021.
Results of a phase 3 trial suggest that brentuximab vedotin (Bv) with doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), and cyclophosphamide (C) should be the new standard frontline therapy among youth with high-risk classic Hodgkin lymphoma (cHL).
At a median follow-up of 12.6 months, the overall response rate was 51.6% and the CR rate was 39.4%.
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.